MADRID, June 21, 2022 /PRNewswire/ — Idoven, a pioneering health tech company advancing early detection and precision medicine of cardiovascular disease, today announced that it has raised $19.8 million in funding. The funding consists of a $12.9 million Series A round co-led by global software investor Insight Partners and Northzone with participation from Wayra. The round […]
Other News
CAPTION HEALTH LAUNCHES FIRST IN-HOME ULTRASOUND SERVICE FOR HEART HEALTH: CAPTION CARE™
Caption Care creates access to echos in partnership with Portamedic’s nationwide mobile clinician network to improve heart health and lower the cost of care BRISBANE, Calif., June 21, 2022 /PRNewswire/ — Caption Health, the AI leader that enables earlier disease detection, today unveiled Caption Care™: America’s first in-home heart wellness assessment and low-cost echo […]
Study Demonstrates Cardiologs’ AI Can Predict Occurrence of Atrial Fibrillation in the Near Future
Newly published research shows that Cardiologs’ deep learning model can predict the short-term risk of atrial fibrillation (AFib) based on 24-hour Holter recordings that show normal sinus rhythm. PARIS and BOSTON, June 21, 2022 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, announced today that its latest study, “Short-term prediction of atrial […]
Berlin Heals Holding AG receives further financing for revolutionary heart implant
ZUG, Switzerland, June 21, 2022 /PRNewswire/ — Berlin Heals Holding AG (Berlin Heals), a Swiss MedTech company that has developed a completely new and groundbreaking method for the therapy of heart failure and has already successfully tested it on patients, informs that the company has raised an additional CHF 5 million in investor funds within […]
VasQ™ External Support Comparative U.S. Study Demonstrated Greater Fistula Primary Patency and Usability with a Lower Intervention Rate
CHARLESTON, S.C., June 21, 2022 /PRNewswire/ — The U.S. VasQ™ External Support Comparative Study results were presented this month for the first time globally at the VASA 2022. The study was a propensity-score matched comparison of the VasQ U.S. Pivotal Study single-arm prospective data with untreated contemporary Medicare patients who underwent arterio-venous fistula […]
Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries
— Successful first two HAV implantations in wounded Ukrainian citizens — HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort — Provides further real-world evidence of the potential of HAV treatment for trauma DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage […]
GE Healthcare Introduces Wireless Patient Monitoring Solution to Help Clinicians Detect Early Patient Deterioration
Continuous monitoring using wearable sensors in general hospital wards may help detect patient deterioration earlier than traditional spot check methods and assist clinicians in improving patient outcomes1. Wireless monitoring allows earlier patient mobilization, a key indicator for recovery, particularly post-surgery2. This innovative technology was developed at GE Healthcare’s global center […]
Conformal Medical Announces Launch of CONFORM Pivotal Trial
Study to support U.S. FDA approval of the novel CLAAS® implant forleft atrial appendage occlusion (LAAO) and stroke prevention NASHUA, N.H., June 17, 2022 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation LAAO technology, today announced the launch of the CONFORM pivotal trial with the enrollment of the first patients at two U.S. sites. The […]
SoniVie receives IDE approval from FDA for its Pilot study to treat Hypertension with its Renal Artery Denervation TIVUS™ technology
TEL AVIV, Israel, June 20, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its “REDUCED1” Pilot study to treat Resistant Hypertension Patients with Renal […]
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
Recent Company Submission in Response to FDA Request Extends PDUFA Date SOUTH SAN FRANCISCO, Calif., June 17, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related […]



